Advanced glycation end-products, anti-hypertensive treatment and diastolic function in patients with hypertension and diastolic dysfunction

European Journal of Heart Failure

Volumn 12, Issue 4, 2010, Pages 397-403

  Hartog, Jasper W L ^a   Van De Wal, Ruud M ^d   Schalkwijk, Casper G ^b   Miyata, Toshio ^c   Jaarsma, Wybren ^d   Plokker, H W Thijs ^d   Van Wijk, Leen M ^e   Smit, Andries J ^a   Van Veldhuisen, Dirk J ^a   Voors, Adriaan A ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^c TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d ST ANTONIUS HOSPITAL   (Netherlands)

^e Refaja Ziekenhuis Stadskanaal   (Netherlands)

Author keywords

Advanced glycation end products; Diastolic function; Hypertension; Skin autofluorescence; Tissue velocity imaging

Indexed keywords

6 N CARBOXYMETHYLLYSINE; ADVANCED GLYCATION END PRODUCT; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; EPROSARTAN; LYSINE DERIVATIVE; N1 (CARBOXYETHYL)LYSINE; PENTOSIDINE; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; AUTOFLUORESCENCE; BIOACCUMULATION; BLOOD PRESSURE REGULATION; CARDIAC PATIENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLE; DIASTOLIC DYSFUNCTION; DOPPLER ECHOCARDIOGRAPHY; DRUG EFFECT; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYPERTENSION; LIQUID CHROMATOGRAPHY; LOADING DRUG DOSE; M MODE ECHOCARDIOGRAPHY; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; MULTICENTER STUDY; OPEN STUDY; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; TREATMENT OUTCOME; TREATMENT RESPONSE; TWO DIMENSIONAL ECHOCARDIOGRAPHY;

ACRYLATES; AGED; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTIHYPERTENSIVE AGENTS; DIASTOLE; FEMALE; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; HYPERTENSION; IMIDAZOLES; LINEAR MODELS; LYSINE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NETHERLANDS; SKIN; STATISTICS AS TOPIC; STATISTICS, NONPARAMETRIC; STROKE VOLUME; THIOPHENES; VENTRICULAR FUNCTION, LEFT;

EID: 77950295233     PISSN: 13889842     EISSN: 18790844     Source Type: Journal    
DOI: 10.1093/eurjhf/hfq001     Document Type: Article

References (24)

1. Hartog JW, Voors AA, Bakker SJ, Smit AJ, van Veldhuisen DJ. Advanced glycation end-products (AGEs) and heart failure: Pathophysiology and clinical implications. Eur J Heart Fail 2007;9:1146-1155.
2. Zile MR, Brutsaert DL. New concepts in diastolic dysfunction and diastolic heart failure: Part II: causal mechanisms and treatment. Circulation 2002;105:1503-1508.
3. Zieman SJ, Kass DA. Advanced glycation endproduct crosslinking in the cardiovascular system: potential therapeutic target for cardiovascular disease. Drugs 2004; 64:459-470.
4. Hartog JW, Voors AA, Schalkwijk CG, Scheijen J, Smilde TD, Damman K, Bakker SJ, Smit AJ, van Veldhuisen DJ. Clinical and prognostic value of advanced glycationend-products in chronic heart failure. Eur Heart J 2007;28:2879-2885.
5. Kass DA, Bronzwaer JG, Paulus WJ. What mechanisms underlie diastolic dysfunction in heart failure? Circ Res 2004;94:1533-1542.
6. Smit AJ, Lutgers HL. The clinical relevance of advanced glycation endproducts (AGE) and recent developments in pharmaceutics to reduce AGE accumulation. Curr Med Chem 2004;11:2767-2784.
7. Hartog JW, Hummel YM, Voors AA, Schalkwijk CG, Miyata T, Huisman RM, Smit AJ, van Veldhuisen DJ. Skin-autofluorescence, a measure of tissue advanced glycation end-products (AGEs), is related to diastolic function in dialysis patients. J Card Fail 2008;14:596-602.
8. Miyata T, van Ypersele dS. Angiotensin II receptor blockers and angiotensin converting enzyme inhibitors: implication of radical scavenging and transition metal chelation in inhibition of advanced glycation end product formation. Arch Biochem Biophys 2003;419:50-54.
9. Saisho Y, Komiya N, Hirose H. Effect of valsartan, an angiotensin II receptor blocker, on markers of oxidation and glycation in Japanese type 2 diabetic subjects: Blood pressure-independent effect of valsartan. Diabetes Res Clin Pract 2006;74:201-203.
10. Monacelli F, Poggi A, Storace D, Durante A, Traverso N, Viviani GL, Odetti P. Effects of valsartan therapy on protein glycoxidation. Metabolism 2006;55: 1619-1624.
11. Busch M, Franke S, Wolf G, Rohde RD, Stein G. Serum levels of the advanced glycation end products N-Carboxymethyllysine and pentosidine are not influenced by treatment with the angiotensin receptor ii type 1 blocker irbesartan in patients with type 2 diabetic nephropathy and hypertension. Nephron Clin Pract 2008;108:c291-c297.
12. Persson F, Rossing P, Hovind P, Stehouwer CD, Schalkwijk C, Tarnow L, Parving HH. Irbesartan treatment reduces biomarkers of inflammatory activity in patients with type 2 diabetes and microalbuminuria: an IRMA 2 substudy. Diabetes 2006;55:3550-3555.
13. Smilde TD, van Veldhuisen DJ, Navis G, Voors AA, Hillege HL. Drawbacks and prognostic value of formulas estimating renal function in patients with chronic heart failure and systolic dysfunction. Circulation 2006;114:1572-1580.
14. Meerwaldt R, Graaff R, Oomen PH, Links TP, Jager JJ, Alderson NL, Thorpe SR, Baynes JW, Gans RO, Smit AJ. Simple non-invasive assessment of advanced glyca-tion endproduct accumulation. Diabetologia 2004;47:1324-1330.
15. Meerwaldt R, Hartog JW, Graaff R, Huisman RJ, Links TP, den Hollander NC, Thorpe SR, Baynes JW, Navis G, Gans RO, Smit AJ. Skin autofluorescence, a measure of cumulative metabolic stress and advanced glycation end products, predicts mortality in hemodialysis patients. J Am Soc Nephrol 2005;16:3687-3693.
16. Teerlink T, Barto R, Ten Brink HJ, Schalkwijk CG. Measurement of Nepsilon-(carboxymethyl)lysine and Nepsilon-(carboxyethyl)lysine in human plasma protein by stable-isotope-dilution tandem mass spectrometry. Clin Chem 2004; 50:1222-1228.
17. Izuhara Y, Miyata T, Saito K, Ishikawa N, Kakuta T, Nangaku M, Yoshida H, Saito A, Kurokawa K, van Ypersele de SC. Ultrapure dialysate decreases plasma pentosi-dine, a marker of "carbonyl stress". Am J Kidney Dis 2004;43:1024-1029.
18. Hartog JW, de Vries AP, Lutgers HL, Meerwaldt R, Huisman RM, van Son WJ, de Jong PE, Smit AJ. Accumulation of advanced glycation end products, measured as skin autofluorescence, in renal disease. Ann NY Acad Sci 2005;1043:299-307.
19. Little WC, Zile MR, Kitzman DW, Hundley WG, O'Brien TX, deGroof RC. The effect of alagebrium chloride (ALT-711), a novel glucose cross-link breaker, in the treatment of elderly patients with diastolic heart failure. J Card Fail 2005;11: 191-195.
20. Thohan V, Koerner MM, Pratt CM, Torre GA. Improvements in diastolic function among patients with advanced systolic heart failure utilizing alagebrium (an oral advanced glycation end-product cross-link breaker). Circulation 2005;112: U620-U620. 2647 Suppl 2.
21. Willemsen S, Hartog JWL, Hummel YM, Posma JL, van Wijk LM, van Veldhuisen DJ, Voors AA. Effects of alagebrium, an advanced glycation end-product breaker, in patients with chronic heart failure: study design and baseline characteristics of the BENEFICIAL trial. Eur J Heart Fail; doi:10.1093/eurjhf/ hfp207. Published online ahead of print 25 January 2010.
22. van Heerebeek L, Hamdani N, Handoko ML, Falcao-Pires I, Musters RJ, Kupreishvili K, Ijsselmuiden AJ, Schalkwijk CG, Bronzwaer JG, Diamant M, Borbely A, van d V, Stienen GJ, Laarman GJ, Niessen HW, Paulus WJ. Diastolic stiffness of the failing diabetic heart: importance of fibrosis, advanced glycation end products, and myocyte resting tension. Circulation 2008;117:43-51.
23. Shapiro BP, Owan TE, Mohammed SF, Meyer DM, Mills LD, Schalkwijk CG, Redfield MM. Advanced glycation end products accumulate in vascular smooth muscle and modify vascular but not ventricular properties in elderly hypertensive canines. Circulation 2008;118:1002-1010.
24. Hartog JW, Willemsen S, Voors AA. Letter regarding article, "Advanced glycation end products accumulate in vascular smooth muscle and modify vascular but not ventricular properties in elderly hypertensive canines". Circulation 2009;119:e233.